Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Treatments Should Be Introduced Gradually To Avoid Later Problems, Says Expert
Concerns over whether the tests a treatment undergoes before release onto the market are enough to ensure its long-term safety are raised in an editorial published by BMJ Clinical Evidence today.
generic viagra online
Health Benefits Tax Gains Support In Congress, Opponents In Business
"You can think of Congress"s efforts to pay for health reform as being a little bit like a battle to slay a many-headed Hydra," writes the New York Times" economic columnist, David Leonhardt. Congress has floated idea after idea for paying for comprehensive health reform, but their proposals have failed to make ends meet because they "do not raise revenue as quickly as health costs rise." Most new taxes - such as a surtax on the rich proposed in the House - increase only as quickly as the economy, while health costs have inflated much more quickly over the last decade.
News of the day
Report Finds Racial Disparities In Prescription Drug Access, Use, Regimen Adherence
"Origins and Strategies for Addressing Ethnic and Racial Disparities in Pharmaceutical Therapy: The Health-Care System, the Provider, and the Patient," National Minority Quality Forum: The report -- by Richard Levy, a health care consultant and former vice president of the National Pharmaceutical Council; Robert Like, professor and director of the Center for Healthy Families and Cultural Diversity of the UMDNJ-Robert Wood Johnson Medical School; and Harry Shabsin, a private-practice psychologist -- looks at how appropriate medications for a variety of diseases often are under-prescribed, over-prescribed, or mis-prescribed among minorities. The report looks at disparities in treatment of minority patients with cardiovascular disease, asthma, psychiatric illness, pain and other conditions and finds disparities in access to medications through insurance programs, in the prescribing of medications and in adherence to medication regimens. The report offers ways to improve prescribing and use of medications among diverse communities (National Minority Quality Forum release, 5/12).
Sexual Health

Aerosolized Nanoparticles Show Promise For Delivering Antibiotic Treatment

Aerosol delivery of antibiotics via nanoparticles may provide a means to improve drug delivery and increase patient compliance, thus reducing the severity of individual illnesses, the spread of epidemics, and possibly even retarding antibiotic resistance. Delivery of antibiotics via nanoparticles has shown promise as a drug delivery mechanism, particularly for controlled release or depot delivery of drugs to decrease the number of doses required to achieve a clinical effect. The effectiveness of this delivery mechanism has not been confirmed directly either in infection models or in patients, but according to new data to be presented on Tuesday, May 19, at the American Thoracic Society"s 105th International Conference in San Diego, this delivery technique appears indeed promising. Carolyn L. Cannon, M.D., Ph.D. from Washington University School of Medicine, and colleagues from the Center for Silver Therapeutics Research at the University of Akron in OH investigated the efficacy of nanoparticle-encapsulated silver-based antibiotics for treating pulmonary infections in a mouse model of pneumonia. Treatment with antibiotic-laden nanoparticles effectively eliminated respiratory infections in mice that had been inoculated with Pseudomona aeroginosa, a common bacterial species that often infects the respiratory tract in humans, particularly immunocompromised patients, ventilated patients or those with cystic fibrosis. Infected mice that inhaled aerosolized nanoparticles encapsulating silver carbene complexes (SCCs), a novel class of silver-based antimicrobials with broad-spectrum activity, showed a significant survival advantage over the control mice that received nanoparticles without the SCCs. Treated mice also had decreased lung bacterial burden and spread, compared to the control mice. Moreover, the treatment with nanoparticles occurred once every 24 hours, a regimen that is known to increase compliance in human patients, versus the usual dosing interval of inhaled antibiotics for P. aeruginosa, which is twice daily. "We were surprised and thrilled to see a 100 percent survival advantage in mice treated daily with SCC22-loaded nanoparticles at doses significantly lower than those used to achieve a similar survival advantage in twice-daily dosing of unencapsulated SCC22. During a 72 hour period, all of the infected control mice died, whereas all of the mice that received just two doses of SCC22-loaded nanoparticles spaced 24 hours apart survived." "My collaborators, Wiley Youngs, Ph.D., and Yang Yun, Ph.D., and I are eager to complete toxicity studies that would enable us to start clinical trials," said Dr. Cannon. "While the mouse studies are tantalizing, the goal that propels our research is realizing the promise of these novel antibiotics and delivery mechanisms through an analogous survival advantage in patients." American Thoracic Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009